Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.54 |
| ▸ | GPR183 | P32249 | 3/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904719 | 1.00 | CCR2 (0.54) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL2899725 | 0.98 | CCR2 (0.54) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL2899723 | 0.98 | CCR2 (0.54) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL2897314 | 0.93 | CCR2 (0.50) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL2903110 | 0.93 | CCR2 (0.54) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL2903112 | 0.93 | CCR2 (0.54) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL2905012 | 0.92 | CCR2 (0.47) | CCR2GPR183SLC2A1PYGL | |
| SCHEMBL2905016 | 0.92 | CCR2 (0.47) | CCR2GPR183SLC2A1PYGL | |
| SCHEMBL2902985 | 0.92 | CCR2 (0.53) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL2902982 | 0.92 | CCR2 (0.53) | CCR2GPR183SLC2A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2010506-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007122103-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | CCR2 8/4885GPR183 86/4885SLC2A1 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.